

## Niles Noblitt appointed Senior Advisor to Episurf Medical

Episurf Medical (NASDAQ: EPIS B) today announces that Niles Noblitt has been named Senior Advisor to the company. On November 12th 2018, Episurf Medical announced that Niles Noblitt would become a new major shareholder of Episurf Medical, subject to approval at an extra general meeting. Niles Noblitt, a US resident, is one of the founders of Biomet, a part of the global orthopaedic market leader Zimmer Biomet. For about 30 years, Niles Noblitt was also the Chairman of Biomet.

*"Episurf Medical's technology is targeting a challenging patient group, so far with a great deal of success. Innovations are driving the development in the orthopaedic industry, and the Episealer® technology is a highly interesting one. I am looking forward to participating in the company's development going forward"* says Niles Noblitt.

As a Senior Advisor to Episurf Medical, Niles Noblitt will assist the company in matters relating to global strategy, partnerships and operational development.

### **For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical  
Tel: +46 (0) 709 62 36 69  
Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

### **About Episurf Medical**

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*

*This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.40 CET on 7 December 2018.*